ScreenerHero

BLTE Belite Bio, Inc

NAS · US · Healthcare · Biotechnology · belitebio.com
156.08USD+0.30%Mkt Cap: 6.29B $P/E: —

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap6.29B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.61M USD
Revenue/Share—
Last Price156.08 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)68.85
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.07
EPS (TTM)-2.69
EPS (Forward)2.26
52W Range
68.2167% of range200.00
52W High200.00 USD
52W Low68.21 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-10.07%
ROA-9.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.99M USD
CapEx (TTM)178.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio33.56
Quick Ratio—
Book Value/Sh19.29 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)228.89 USD
Upside (mean)+46.6%
Target Range185.00 USD – 303.00 USD
185.00+46.6% to mean303.00
# Analysts9
Ownership
Shares Out.40.27M
Float19.55M
Insiders43.64%
Institutions24.27%
Short Interest
Short Ratio5.1d
Short % Float5.00%
Short % Out.2.61%
Shares Short1.05M
Short (prev mo.)1.12M
Technical
SMA 50165.79 (-5.9%)
SMA 200161.01 (-3.1%)
Beta-1.23
S&P 52W Chg16.45%
Avg Vol (30d)186.90K
Avg Vol (10d)167.42K
Technical Indicators
RSI (14)39.6
MACD-2.2479
MACD Signal-0.0635
MACD Hist.-2.1844
BB Upper187.14 USD
BB Middle169.41 USD
BB Lower151.69 USD
BB Width20.92%
ATR (14)6.237 USD
Vol Ratio (20d)0.49x